Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248693 | 0.85 | MAOB (0.66) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL8549374 | 0.84 | FFAR1 (0.60) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL22874523 | 0.84 | MAOB (0.62) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL13232461 | 0.84 | GRM5 (0.62) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL1247999 | 0.83 | MAOB (0.63) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL14163905 | 0.83 | FFAR1 (0.63) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL863622 | 0.82 | FFAR1 (0.58) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL1250474 | 0.81 | ALOX5 (0.63) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL28558200 | 0.81 | MAOB (0.76) | FFAR1FFAR4MAOBMAOAMRGPRX4 | |
| SCHEMBL21340514 | 0.80 | FFAR1 (0.56) | FFAR1FFAR4MAOBAPPMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | FFAR1 358/4885FFAR4 747/4885MAOB 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.